Skip to main content

Table 1 Clinical trials with chemotherapeutic agents causing replication stress used in ovarian cancer treatment. [clinicaltrials.gov] *not applicable

From: Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer

TargetName of drug/drugsObjective of trialClinical trial phaseClinical trial identifier
PARPBMN 673 (talazoparib)Patients with deleterious BRCA 1/2 mutation-associated ovarian cancer who have had prior PARP inhibitor treatment2NCT02326844
PARPBSI-201 (iniparib)
Carboplatin/
gemcitabine
Patients with platinum-resistant recurrent ovarian cancer2NCT01033292
PARPAZD2281 (olaparib)Study to assess the efficacy and safety of a PARP inhibitor for the treatment of BRCA-positive advanced ovarian cancer2NCT00494442
PARPCediranib
Olaparib
Patients with ovarian cancer whose cancer worsened despite previously receiving a PARP inhibitor (such as olaparib)–*NCT02681237
PARPRucaparib
Nivolumab
Treatment following response to frontline treatment in newly diagnosed ovarian cancer patient3NCT03522246
ATR
PARP
AZD6738
Olaparib
ATARI trial test: ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib in patients with relapsed gynaecological cancers with an abnormality in ARID1A gene2NCT04065269
WEE1MK-1775
Carboplatin
Patients with p53 mutated epithelial ovarian cancer that have been treated with first line treatment (paclitaxel–carboplatin combination therapy) and that have shown early relapse (within 3 months)2NCT01164995
ATR
PARP
AZD6738
Olaparib
Combination ATR and PARP inhibitor (CAPRI) trial with AZD 6738 and olaparib in recurrent ovarian cancer2NCT03462342
ATRAZD6738
Paclitaxel
Refractory cancer patients who have failed to standard-of-care chemotherapy1NCT02630199
ATRM6620
Avelumab
Carboplatin
In participants with PARPi-resistant, recurrent, platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer2NCT03704467
ATRM6620
Gemcitabine
Patients with recurrent ovarian, primary peritoneal or fallopian tube cancer2NCT02595892
ATRM6620
Topotecan
In small cell cancers and extrapulmonary small cell cancers2NCT02487095
ATRM6620
Carboplatin, gemcitabine
Adult women with platinum-sensitive, recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal or fallopian tube cancer2NCT02627443
ATRM6620
Avelumab
Nedisertib
DDR-deficient metastatic or unresectable solid tumors1NCT04266912
ATRM6620
Carboplatin
Gemcitabine
Patients with recurrent and metastatic ovarian, primary peritoneal or fallopian tube cancer2NCT02627443
ATRBAY 1895344Patients with advanced solid tumors and lymphomas1NCT03188965
ATR
PARP
BAY 1895344
Niraparib
Advanced solid tumors and ovarian cancer1NCT04267939
ATRVX-803 (M4344)Women with recurrent ovarian cancer that has progressed while on a PARP inhibitor1NCT02278250
ATR
PARP
VX-803 (M4344)
Niraparib
Women with recurrent ovarian cancer that has progressed while on a PARP inhibitor1NCT04149145
ATR
PARP
AZD 6738
Olaparib
HR-deficient patients with/without additional mutations in ATM, CHK-2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC2NCT02576444
CHK1
PARP
Prexasertib (LY2606368)
Olaparib
Solid tumors1NCT03057145
CHK1Prexasertib (LY2606368)BRCA1/2 mutation-associated breast or ovarian cancer, triple negative breast cancer and HGSOC2NCT02203513
CHK1Prexasertib (LY2606368)Patients with platinum-resistant or refractory ovarian cancer2NCT03414047
\